Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

MA Tincopa, R Loomba - The Lancet Gastroenterology & Hepatology, 2023 - thelancet.com
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent form of chronic liver disease
that poses challenges in diagnosis and risk stratification. Non-alcoholic steatohepatitis …

Biomarkers in stress related diseases/disorders: diagnostic, prognostic, and therapeutic values

K Dhama, SK Latheef, M Dadar, HA Samad… - Frontiers in molecular …, 2019 - frontiersin.org
Various internal and external factors negatively affect the homeostatic equilibrium of
organisms at the molecular to the whole-body level, inducing the so-called state of stress …

Advances in non-invasive assessment of hepatic fibrosis

R Loomba, LA Adams - Gut, 2020 - gut.bmj.com
Liver fibrosis should be assessed in all individuals with chronic liver disease as it predicts
the risk of future liver-related morbidity and thus need for treatment, monitoring and …

[HTML][HTML] New biomarkers in liver fibrosis: a pass through the quicksand?

M Tagliaferro, M Marino, V Basile, K Pocino… - Journal of Personalized …, 2024 - mdpi.com
Chronic liver diseases (CLD) stem from various causes and lead to a gradual progression
that ultimately may result in fibrosis and eventually cirrhosis. This process is typically …

Biomarkers of cholestasis

A Pieters, E Gijbels, B Cogliati, P Annaert… - Biomarkers in …, 2021 - Taylor & Francis
Cholestasis is a major pathological manifestation, often resulting in detrimental liver
conditions, which occurs in a variety of indications collectively termed cholestatic liver …

The role of noninvasive biomarkers for monitoring cell injury in advanced liver fibrosis

R Riccardo, F Cinque, K Patel… - Expert Review of …, 2025 - Taylor & Francis
Introduction Accurate and reliable diagnosis and monitoring of hepatic fibrosis is
increasingly important given the variable natural history in chronic liver disease (CLD) and …

Quantitative ELISA for SERPINA4/kallistatin

KN Shashidhar, V Lakshmaiah, C Muninarayana… - …, 2021 - Taylor & Francis
Background: SERPINA4/kallistatin is a multifunctional protein expressed from the liver; its
concentration in blood circulation reflects the degree of liver dysfunction and may serve as a …

Diagnosis of liver fibrosis using digital analysis

A Kleczka, B Mazur, K Tomaszek… - Journal of …, 2023 - diagnostykalaboratoryjna.eu
Liver fibrosis is a pathological process in which excessive deposition of connective tissue
occurs in the liver. It is a response to chronic liver damage caused by viral agents, alcohol …

Screening and Clinical Verification of Extracellular Vesicle Biomarkers

B Li, Y Huang, B Wu, H Lin, Q Xiu, Q Wang… - … Vesicles: From Bench to …, 2024 - Springer
Extracellular vesicles (EVs), lipid bilayer-encapsulated membrane particles carrying
proteins, lipids, nucleic acids, and sugars, are shed by most cells into the extracellular milieu …

[PDF][PDF] Cirrhosis of liver: comparative cross reactivity for quantification of SERPINA4/Kallistatin

KN Shashidhar, V Lakshmaiah, C Muninarayana… - J. Clin. Lab …, 2021 - researchgate.net
Cirrhosis of liver is an end stage of chronic liver insults from varied etiologies which leads to
impaired liver functions. Proteins expressed from liver and enters into circulation reflects …